Maintenance with niraparib (Zejula, GlaxoSmithKine) plus ipilimumab (Yervoy, Bristol Myers Squibb) was effective in preventing progression in patients with advanced pancreatic cancer and led to a PFS of approximately 8 months, Reiss, assistant professor of medicine at the Hospital of the University of Pennsylvania, said. In comparison, niraparib plus nivolumab (Opdivo, Bristol Myers Squibb) was…
Brown, chief fellow in the division of hematology and oncology at Penn Medicine, said the small, descriptive study, which evaluated 42 patients and was presented as part of a poster session at ASCO Annual Meeting, found that chemotherapy does retain some activity for this patient population. Read more . . .
This review explores the processes underpinning the influence of smoking-related chemicals on fibrosis and inflammation and provides insight into the etiology of PC. In the future, a thorough exploration of the effects of smoking chemicals on the activity of pancreatic stem cells and then on the essential mediators of the association with cancer cells would…
In a recent paper published in Frontiers in Physiology, the researchers used histopathological analyses, genetically engineered animal models and human samples to quantify the subtypes of EECs throughout the development of pancreatic tumors. This work acknowledged the diversity within this cell population and sought to understand how different quantities of each EEC subtype could contribute to disease progression. Read…
Individuals recommended for pancreas surveillance were prospectively enrolled into one of eight CAPS5 study centers between 2014 and 2021. The primary end point was the stage distribution of pancreatic ductal adenocarcinoma (PDAC) detected (stage I v higher-stage). Overall survival was determined using the Kaplan-Meier method. Read more . . .
Homologous recombination deficiency, high tumor mutation burden and microsatellite instability-high disease also appeared more common in the KRAS wild-type population.In addition, early-onset pancreatic cancers — those diagnosed before age 50 years — appeared more likely to be KRAS wild-type, exhibit homologous recombination deficiency phenotype and have germline BRCA1/BRCA2 alterations. Read more . . .
The study looked at 8,490 patients from Wisconsin who were diagnosed with pancreatic ductal adenocarcinoma from 2004 through 2017, the cancer center explained. The study estimates 950 Wisconsinites died of the disease in 2020. White patients lived for over 9 months after they were diagnosed, while Black patients lived for over 8 months. Read more…
“Our findings show, for the first time, how aerobic exercise affects the immune microenvironment within pancreatic tumors,” noted lead author Emma Kurz, MD, PhD, from at the NYU Grossman School of Medicine, New York. Read more . . .
The National Cancer Institute (NCI), the Early Detection Research Network (EDRN), and the Japan Agency for Medical Research and Development (AMED) hold an annual USA-Japan Workshop on Biomarkers for Cancer Early Detection. The 7th USA-Japan Workshop was held at the Ito International Research Center at the University of Tokyo in January 2020.Read more . .…
In the open label, multi-center study, investigators evaluated CT041, a CAR T-cell therapy that targets Claudin18.2 (CLDN18.2).Heavily pretreated patients in the population were able to achieve responses up to 60% in the salvage line setting, Botta says. Moreover, patients who have been on multiple lines of chemotherapy and present with various comorbidities were able to…